Zacks Research Issues Optimistic Forecast for CRL Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities researchers at Zacks Research lifted their Q4 2025 earnings per share estimates for shares of Charles River Laboratories International in a note issued to investors on Monday, February 2nd. Zacks Research analyst Team now anticipates that the medical research company will earn $2.32 per share for the quarter, up from their prior forecast of $2.31. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q1 2026 earnings at $2.39 EPS, Q4 2026 earnings at $2.92 EPS, Q1 2027 earnings at $2.43 EPS and Q4 2027 earnings at $3.25 EPS.

Several other research firms have also commented on CRL. Weiss Ratings reiterated a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, January 21st. Robert W. Baird set a $224.00 price target on shares of Charles River Laboratories International in a report on Friday, January 9th. Bank of America raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective for the company in a research note on Monday, December 15th. Citigroup lifted their price objective on Charles River Laboratories International from $200.00 to $265.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Finally, Barclays increased their target price on Charles River Laboratories International from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Ten analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $209.46.

Charles River Laboratories International Stock Down 5.6%

Charles River Laboratories International stock opened at $201.38 on Wednesday. Charles River Laboratories International has a fifty-two week low of $91.86 and a fifty-two week high of $228.88. The firm has a market capitalization of $9.91 billion, a price-to-earnings ratio of -129.09, a price-to-earnings-growth ratio of 6.40 and a beta of 1.63. The stock’s fifty day moving average is $203.56 and its two-hundred day moving average is $179.31. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.37.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.11. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.Charles River Laboratories International’s revenue was down .5% on a year-over-year basis. During the same period in the previous year, the firm posted $2.59 earnings per share.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Tema Etfs LLC purchased a new stake in shares of Charles River Laboratories International in the fourth quarter valued at $26,000. Neo Ivy Capital Management acquired a new stake in Charles River Laboratories International in the 2nd quarter worth about $29,000. Rothschild Investment LLC boosted its stake in Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after buying an additional 84 shares during the last quarter. Atlantic Union Bankshares Corp purchased a new stake in Charles River Laboratories International in the 3rd quarter valued at about $31,000. Finally, Activest Wealth Management increased its stake in shares of Charles River Laboratories International by 10,900.0% during the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 218 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.